When counselling patients for postexposure prophylaxis after sexual exposure, we may need to inform them that the efficacy may be low, especially if the patient also had risks prior to the 72 hours between exposure and treatment. The use of a point-of-care test, as well as fourth generation HIV tests and HIV RNA in combination, can still miss seroconversion in the ‘eclipse’ phase of the infection as these tests are not designed to detect the earliest phase of infection.
FisherM, BennP, EvansB, Clinical Effectiveness Group (BASHH). UK Guideline for the use of post-exposure prophylaxis for HIV following sexual exposure. Int J STD AIDS2006;17:81–92
2.
WinterAJ, SulaimanZ, HawkinsD, the BASHH HIV Clinical Governance Committee. BASHH Clinical Governance Committee guidance on the appropriate use of HIV point of care tests. Int J STD AIDS2006;17:802–05
3.
See http://www.ukneqas.org.uk/content/Pageserver.asp (last accessed 2 November 2011)
4.
Siemens Healthcare Diagnostics Inc. ADVIA Centaur and ADVIA Centaur XP Assay Manual. HIV Ag/Ab Combo (CHIV) Assay. Assay for the Detection of HIV p24 Antigen and Antibodies to Human Immunodeficiency Virus Type 1, Including Group O (HIV-1 + ‘O’) and/or Type 2 (HIV-2). Bayswater: Siemens Healthcare Diagnostics Inc, 2008
5.
BarbaraJ, RamskillS, PerryK, The National Blood Service (England). Approach to evaluation of kits for detecting infectious agents. Transfus Med Rev2006;21:147–58
6.
FoxJ, DunnH, O'SheaS. Low rates of p24 antigen detection using a fourth-generation point of care HIV test. Sex Transm Infect2011;87:178–79
7.
RolandME, NielandsTB, KroneMR, Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis2005;41:1507–13
8.
SteklerJ, MaenzaJ, StevensCE, Screening for acute HIV infection: lessons learned. Clin Infect Dis2007;44:459–61
SPARTAC trial. See http://www1.imperial.ac.uk/departmentofmedicine/divisions/infectiousdiseases/infectious_diseases/hiv_trials/spartac/ (last checked 20 February 2011)
